Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KPS-0373 in Spinocerebellar Degeneration
NCT01970098Phase 3Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Oct 2013
- Primary completion
- Jan 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rovatirelin in spinocerebellar degeneration (SCD) (3 arms), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoint: Scale for the Assessment and Rating of Ataxia at 24 weeks. Started Oct 2013; status: completed.
02
Drugs
rovatirelin
03
Conditions
spinocerebellar degeneration (SCD)
Beyond the preview
Go deeper on NCT01970098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01970098.